Abnormally Short Activated Partial Thromboplastin Times Are Related to Elevated Plasma Levels of TAT, F1+2, D-Dimer and FVIII:C
Abstract
Abnormally short activated partial thromboplastin times (APTTs) are associated with an increased risk of thrombotic disorders. We have examined the status of coagulation activity in subjects with short APTTs. In addition, the presence of the thrombotic risk factors G1691A-factor V, G20210A-prothrombin gene mutation and factor VIII coagulant activity (FVIII:C) was determined. Plasma levels of TAT, F1+2, D-dimer and FVIII:C were markedly higher in subjects with short APTTs compared with subjects with normal APTTs. APTTs were inversely related to TAT, F1+2, D-dimer and FVIII:C levels. The prevalence of G1691A-factor V and G20210A-prothrombin gene mutation between the group with short APTTs and the control group was not significantly different. Hence, these gene polymorphisms do not contribute to the increased risk of thrombosis associated with short APTTs. In conclusion, short APTTs are indicative of marked coagulation activity and elevated FVIII:C levels. Elevated FVIII:C levels may play a pathogenic role in the increased risk of thrombosis associated with abnormally short APTTs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
During an acute thrombotic event, raised factor VIII levels can shorten activated partial thromboplastin time (aPTT), producing false-negative LA screening by aPTT tests.
“During an acute thrombotic event, the raising of factor VIII levels can shorten activated partial thromboplastin time (aPTT), producing false-negative LA screening by aPTT tests [19]”
From Lupus Anticoagulant Detection under the Magnifying Glass (2023) · cites this paper as [19]
Cites
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., & Eichinger, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430702 · Cited by 763 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
ten Boekel, E., Böck, M., Vrielink, G.-J., Liem, R., Hendriks, H., & Kieviet, W. D. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.05.006 · Cited by 40 · see citing works
Lupus Anticoagulant Detection under the Magnifying Glass
Molinari, A. C., Martini, T., Banov, L., Ierardi, A., Leotta, M., Strangio, A., & Santoro, R. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206654 · Cited by 9 · see citing works
Analytical dilemmas in lupus anticoagulant detection
Moore, G. W. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00104 · Cited by 5 · see citing works
- Authors
- ten Boekel, E., & Bartels, P.
- Venue
- Pathophysiology of Haemostasis and Thrombosis
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 32
- Issue
- 3
- Pages
- 137-142
- ISSN
- 1424-8832 (ISSN-L)
- 1424-8840
- OpenAlex
- W2001692920
- Cited by
- 51
- References
- 1
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 2 · 2018: 1 · 2016: 3 · 2015: 5 · 2014: 2 · 2013: 1 · 2012: 3
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pathophysiology of Haemostasis and Thrombosis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Blood properties and coagulation
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- activated partial thromboplastin time, thrombosis risk, tissue factor, factor Xa, D-dimer, factor VIII coagulant activity, factor V Leiden, prothrombin G20210A, coagulation activation, thrombotic disorders
- MeSH terms
- Antithrombin III, Factor V, Factor VIII, Fibrin Fibrinogen Degradation Products, Gene Frequency, Humans, Partial Thromboplastin Time, Peptide Fragments, Peptide Hydrolases, Promoter Regions, Genetic, Prospective Studies, Prothrombin, Risk Factors, Cohort Studies, Prevalence, Thrombophilia, Activated Protein C Resistance, Genetic Predisposition to Disease, 3' Untranslated Regions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
